Active Substance: Lapatinib (as ditosylate monohydrate).
Overview
Welcome to Dwaey, specifically on TYKERB 250mg page.
This medicine contains an important and useful components, as it consists of
Lapatinib (as ditosylate monohydrate)is available in the market in concentration
Lapatinib
Evaluate left ventricular ejection fraction (LVEF) prior to treatment. Moderate or severe hepatic impairment. Patients who have or may develop QTc prolongation, including those w/ hypokalaemia or hypomagnesemia. Monitor liver function & pulmonary symptoms indicative of interstitial lung disease/pneumonitis. Pregnancy & lactation. Lactation: Do not nurse
Breast cancer
Hypersensitivity to lapatinib ditosylate
>10% (lapatinib+capecitabine) Diarrhea (65%),Anemia (56%),Hand-foot synd (53%),Increased LFTs (37-49%),Nausea (44%),Rash (28%),Vomiting (26%),Pain (23%),Neutropenia (22%),Thrombocytopenia (18%),Mucositis (15%),Stomatitis (14%),Dyspnea (12%),Dyspepsia (11%),Insomnia (10%) 1-10% Insomnia
4
Kinase inhibitor, blocks EGF-receptor HER2 kinase; tyrosing kinase inhibition possibly blocks angiogenesis and cellular proliferation.
Increased conc w/ CYP3A4 inhibitors (eg ketoconazole, itraconazole or grapefruit juice), midazolam, irinotecan & digoxin. Decreased conc w/ CYP3A4 inducers (eg rifampin, carbamazepine, phenytoin) & proton-pump inhibitors (eg esomeprazole). Altered pharmacokinetics w/ P-glycoprotein, breast cancer resistance protein (BCRP) inhibitors & inducers, topotecan & rosuvastation. Increased incidence & severity of adverse events w/ paclitaxel & docetaxel. CYP3A4 or CYP2C8 substrates.
Information not available